CLINICAL TRIAL: REVEAL II

临床试验：REVEAL II

• 批准号: 7951422
• 负责人: Thomas O Obisesan
• 金额: $ 3.96万
• 依托单位: HOWARD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951422
• 关键词: Age; Anxiety; Biological Markers; Clinical; Clinical Research; Clinical Trials; Complex; Computer Retrieval of Information on Scientific Projects Database; Consensus; Data; Degenerative Disorder; Development; Environmental Exposure; Family history of; Funding; Gender; Genes; Genetic Markers; Genetic Predisposition to Disease; Grant; Individual; Institution; Marketing; Predisposition; Public Policy; Race; Research; Research Personnel; Resources; Risk; Source; Susceptibility Gene; Testing; United States National Institutes of Health; Universities; interest; late disease onset; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Genes and other biological markers are rapidly being identified that can provide presymptomatic estimates or risk to individuals for the eventual development of complex late-onset diseases. Many of the recently discovered genetic markers are not deterministic genes, but rather susceptibility genes that interact with other, as yet unidentified genes, and with factors such as age, gender, race, family history and environmental exposures. There is widespread public interest in obtaining risk information, and a broad consensus that treatments will soon be developed to slow or prevent the onset of degenerative disease. With few restrictions on the marketing and utilization of genetic susceptibility tests, their use may soon increase. Nevertheless, there are little or no data available to understand who( e.g., age, gender, race) will seek genetic susceptibility risk information once it is available; and why they would do so (e.g. to obtain treatment , to alleviate anxiety, to prepare financially). Even more importantly, there is little information on the potential benefits or negative consequences of providing susceptibility risk information that could guide rational clinical decisions or public policy.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 正在迅速确定基因和其他生物标记物，可以为个人最终发展复杂的晚发疾病的发展提供预症状的估计或风险。 许多最近发现的遗传标记不是确定性基因，而是与其他尚未确定的基因相互作用的易感基因，以及年龄，性别，种族，家族史和环境暴露等因素。 在获得风险信息方面，公众有广泛的兴趣，并且广泛共识，即很快就会开发治疗以减缓或防止退行性疾病的发作。 由于对遗传易感性测试的营销和利用很少限制，它们的使用可能很快就会增加。 然而，几乎没有数据可以理解谁（例如，年龄，性别，种族）一旦获得遗传易感性风险信息；以及为什么他们这样做（例如，要获得治疗，减轻焦虑，以便在经济上做好准备）。 更重要的是，关于提供易感风险信息的潜在收益或负面后果的信息很少，这些信息可以指导理性的临床决策或公共政策。